Amarox Recalls Sertraline Batch Due to Packaging Error Involving Antidepressants
Amarox, a subsidiary of the Indian drugmaker Hetero Group, is recalling a batch of sertraline after mistakenly packaging it with a blister strip of another antidepressant, citalopram. The UK Medicines and Healthcare products Regulatory Agency (MHRA) announced the recall after a patient complaint revealed the error. The recall affects 100 mg film-coated tablets of sertraline, a selective serotonin reuptake inhibitor (SSRI). The error occurred during secondary packaging at the manufacturing facility. Healthcare professionals are advised to quarantine remaining stock and return it to suppliers. Pharmacists are instructed to contact patients who received the recalled product, especially those who received it in the past 28 days. The MHRA warns that concurrent exposure to two SSRIs may increase serotonergic effects, posing risks to patients, particularly those with pre-existing cardiac conditions or those taking other serotonergic medications. 
